News
Medindia on MSN2h
FDA Approves ENFLONSIA to Shield Infants From RSVIn a major boost for infant health, the U.S. Food and Drug Administration (FDA) has approved ENFLONSIA (clesrovimab-cfor) , a ...
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...
A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...
Merck’s Enflonsia (clesrovimab) has received US Food and Drug Administration (FDA) approval for the prevention of respiratory ...
Scripps News on MSN21h
FDA Approves Merck’s Enflonsia to prevent RSV in infantsThe Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...
Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
The Food and Drug Administration (FDA) has approved Enflonsia ™ (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who ...
Enflonsia is the first FDA-approved respiratory syncytial virus (RSV) preventative for infants, regardless of weight, according to the news release.
Pharmaceutical Technology on MSN3d
MSD receives FDA approval for Enflonsia to prevent RSVMSD has received FDA approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) in neonates and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback